Astellas Pharma - About the company
Astellas Pharma is a public company based in Chiba (Japan), founded in 1923. It operates as a Manufacturer of generic products. Astellas Pharma has raised an undisclosed amount in funding. The company has 142 active competitors, including 7 funded and 52 that have exited. Its top competitors include companies like Abbott, Shanghai Henlius Biotech and Pierre Fabre.
Company Details
Astellas Pharma is a manufacturer of generic pharma medicines. The company is focused on the development, manufacture, and sale of its pharmaceuticals to both domestic and overseas markets including Japan, North America, Europe, and Asia. In 2022, the company recorded annual revenues of $11.21B and a net profit of $0.73B.
- Website
- www.astellas.com/en
- Social
- Phone Number
- +81 **********
- Registered Address
- 15, Arne Jacobsens Allé, København S, 2300, None
Key Metrics
Founded Year
1923
Location
Chiba, Japan
Stage
Public
Latest Funding Round
Investors
Ranked
17th among 142 active competitors
Annual Revenue
$0 - $1M as on Dec 31, 2014
Employee Count
12,626 as on Sep 30, 2026
Investment & Acquisitions
Exit Details
Public
Legal entities associated with Astellas Pharma
Astellas Pharma is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ASTELLAS PHARMA A/S CIN: 10888638 , Denmark, Active | Jul 01, 1987 | - | - | |
ASTELLAS PHARMA (THAILAND) COMPANY LIMITED CIN: 0105542002586 , Thailand, Active | Jan 12, 1999 | $10M - $50M (As on Dec 31, 2023) | - | |
Ocata Therapeutics, Inc. CIN: 1140098 , United States, Active | $0 - $1M (As on Dec 31, 2014) | - | - | |
ASTELLAS PHARMA INDIA PRIVATE LIMITED CIN: U85192MH2008FTC188194 , India, Active | Nov 14, 2008 | ₹50 - ₹100 Cr (As on Mar 31, 2025) | 64 (As on Oct 31, 2024) |
Astellas Pharma's IPO details
Astellas Pharma got listed on May 16, 1949.
Click here to take a look at Astellas Pharma's IPO in detail
Sign up to download Astellas Pharma's company profile
Astellas Pharma's funding and investors
Astellas Pharma has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Jul 22, 2020 for $*****. 1 investor participated in its latest round. Astellas Pharma has 5 institutional investors.
Here is the list of recent funding rounds of Astellas Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 22, 2020 | 7064280 | Grant (prize money) | 9990448 | 6694277 | 7266863 | 4399164 |
Access funding benchmarks and valuations. Sign up today!View details of Astellas Pharma's funding rounds and investors
Astellas Pharma's founders and board of directors
Founder? Claim ProfileAstellas Pharma's employee count trend
Astellas Pharma has 12,626 employees as of Sep 26. Here is Astellas Pharma's employee count trend over the years:
Uncover Astellas Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Astellas Pharma's Competitors and alternates
Top competitors of Astellas Pharma include Abbott, Shanghai Henlius Biotech and Pierre Fabre. Here is the list of Top 10 competitors of Astellas Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Abbott 1888, Libertyville (United States), Public | Developer of medical devices, generic pharmaceuticals, and nutrition products | - | 73/100 | |
2nd | Shanghai Henlius Biotech 2010, Xuhui (China), Public | Biotech arm of Fosun with a focus of Monoclonal Antibodies | $347M | 69/100 | |
3rd | Pierre Fabre 1962, Castres (France), Funding Raised | Provider of pharma, dermo-cosmetics, OTC and consumer health products | - | 67/100 | |
4th | Natco Pharma 1981, Hyderabad (India), Public | Developer and manufacturer of API and finish dosage forms | - | 66/100 | |
5th | Akumentis Healthcare 2010, Thane (India), Series A | Manufacturer of pharmaceutical products across multiple therapeutic areas | $18.9M | 66/100 | |
6th |  Boehringer Ingelheim 1885, Ingelheim am Rhein (Germany), Funding Raised | Provider of generic drugs and clinical research services | - | 65/100 | |
7th |  Corona Remedies 2004, Ahmedabad (India), Public | Manufacturer of pharmaceutical products focused on women's health, cardio-diabetology, pain management, and urology | $14.9M | 64/100 | |
8th | Provider of pharmaceutical products | $45.6M | 63/100 | ||
9th | Developer of affordable therapeutics and provider of e-commerce pharmacy services | - | 63/100 | ||
10th | Developer of pharmaceutical therapies for various therapeutic areas | - | 63/100 | ||
17th | Astellas Pharma 1923, Chiba (Japan), Public | Manufacturer of generic products | - | 56/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Astellas Pharma's competitors? Click here to see the top ones
Astellas Pharma's Investments and acquisitions
Astellas Pharma has made 5 investments in companies including Poseida Therapeutics and Taysha Gene Therapies. Astellas Pharma has also acquired 15 companies including Propella Therapeutics and IVERIC bio.Here is the list of investments & acquisitions:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Dec 22, 2023 | Acquisition | 2020 | Pittsboro (United States) | |
Aug 07, 2023 | Investments | 2015 | San Diego (United States) | |
Apr 29, 2023 | Acquisition | 2007 | New York City (United States) |
Want to know more about where corporates are investing? Sign up today!See all investments and acquisitions by Astellas Pharma
Reports related to Astellas Pharma
Here is the latest report on Astellas Pharma's geography:
News related to Astellas Pharma
Filter this listMedia has covered Astellas Pharma for a total of 44 events in the last 1 year, 21 of them have been about company updates and 7 about partnerships.
•
Astellas acquires option rights for Australian cancer drug candidateNikkan•Oct 29, 2026•Astellas Pharma
•
Astellas and Audax Biosciences Enter Option and License Agreement for Novel Immuno-Oncology CandidatePR Newswire•Oct 28, 2026•Astellas Pharma
•
AI Proteins and Astellas sign miniprotein therapeutics dealPharmaceutical Technology•Oct 22, 2026•Astellas Pharma
•
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung CancerThe Associated Press•Sep 23, 2026•Astellas Pharma
•
Astellas Enters Voluntary Agreement with U.S. Government Supporting Affordable Access to MedicinesPR Newswire•Sep 01, 2026•Astellas Pharma
•
•
Russia to test first generic of Astellas' menopause drug VeozahAug 19, 2026•Astellas Pharma
•
2026 Q2: Astellas Pharma Sees Strong Revenue, Cost Control & Share‑Buyback SuccessAktiensensor•Aug 13, 2026•Astellas Pharma
•
Astellas Pharma ADR GAAP EPS of ¥78.96, revenue of ¥640.91B; reaffirms FY 2027 outlookSeeking Alpha•Aug 05, 2026•Astellas Pharma
•
MTU Launches New Master of Engineering in Integrated Manufacturing EngineeringBusinessplus•Jun 29, 2026•Astellas Pharma, Munster Technological University
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Astellas Pharma
Explore our recently published companies
- Homeschool Facts - Unfunded company
- Canbas Bio - Tangerang based, 2018 founded, Unfunded company
- BioNordika - Finland based, 1995 founded, Public company
- Shangkentech.com - 2018 founded, Unfunded company
- Innovsense.com - 2022 founded, Unfunded company
- Jupho - Mumbai based, Unfunded company
